Compare Incyte Corporation (INCY) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Invesco Preferred ETF — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Invesco Preferred ETF trades at $10.01 (market cap $3.60B). The key difference: Incyte Corporation is far larger — about 6.3× Invesco Preferred ETF's market cap, and Incyte Corporation is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Invesco Preferred ETF for 95 Days on average.
| INCY | PGX | |
|---|---|---|
Market Cap | $22.85B | $3.60B |
Volume | 1,927,029 | 5,986,026 |
Sector | Health | — |
52-Week High | $129.93 | $11.61 |
52-Week Low | $83.80 | $9.97 |
Typical Hold Time | 33 Days | 95 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
PGX trades at $10.03, up 0.6% today, with a bearish technical outlook as moving averages signal strong selling pressure. Key support and resistance cluster at $10. The company has scheduled dividends for July and September 2026 at $0.06 per share, but financial ratios like P/E and P/S are unavailable, limiting fundamental visibility.
The stock faces headwinds from weak technical momentum and a lack of current financial data, though dividend payments provide some income appeal. Risks include reliance on outdated metrics and market sensitivity. Investors need updated earnings reports to assess valuation and growth prospects accurately.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
